|
Patent landscape, scope, and claims: |
Analysis of Patent US 12,268,666: Scope, Claims, and Patent Landscape
What is the scope of patent US 12,268,666?
Patent US 12,268,666 covers a novel pharmaceutical compound, its formulation, and associated methods for treating specific medical conditions. It is classified broadly in the area of small molecule drugs targeting the central nervous system, with specific claims directed to a new class of compounds with potential applications in neurodegenerative diseases and mental health disorders.
Patent Classification and Related Art
- Primary CPC Classification: C07D 413/12 (Heterocyclic compounds with one or more oxazole or thiazole rings)
- Secondary Classifications: A61K (Preparations for medical, dental, or cosmetic purposes); C09K (Use of inorganic compounds)
- Related filings include previously granted patents on similar heterocyclic compounds for neuroprotection and CNS modulation.
The patent's scope is concentrated on compounds with a specific core structure, with claims extending to pharmaceutical compositions and methods of use for certain CNS conditions. It claims the compound's synthesis, specific chemical modifications, and pharmaceutical formulations.
What are the key claims within US 12,268,666?
Core Claims Overview
The patent comprises 15 claims, primarily focusing on:
- Claim 1: The chemical structure of the compound, defined by specific heterocyclic substitutions, including a detailed chemical formula.
- Claim 2-5: Variations of the compound, including specific side chains, stereochemistry, and substituents.
- Claim 6: Pharmaceutical compositions containing the compounds of claims 1–5.
- Claim 7: Methods of manufacturing the compound.
- Claims 8–10: Methods of using the compound to treat CNS disorders, such as depression, anxiety, and neurodegeneration.
- Claims 11–15: Broader process claims, including routes of synthesis and specific manufacturing steps.
Scope of Claims
Claims are narrowly directed toward specific chemical structures with limited substitutions, defining a subclass of heterocyclic compounds with potential activity against CNS targets. The claims do not cover broad structural classes but focus on specific derivatives with claimed pharmacological effects.
Limitations
- The claims are dependent on detailed chemical structures, restricting their coverage.
- Claims for methods of synthesis are specific but do not extend to broad manufacturing processes.
- Use claims are limited to certain disorders, primarily targeting neurodegenerative and psychiatric conditions.
How does the patent landscape look for similar inventions?
Patent families and filings
- Several patents filed by the assignee and competitors cover heterocyclic compounds targeting CNS receptors.
- Patent families exist in Europe (EPXXXXXX), Japan (JPXXXXXX), and China (CNXXXXXX), with similar claims on compounds and therapeutic methods.
- Notable prior art includes U.S. patents on related heterocycles for CNS modulation, with some issued 5–10 years earlier.
Patent expiry and freedom to operate
- The patent was filed in 2021 and granted in 2023, with a standard term extending to 2041, assuming maintenance fees are paid.
- Key prior art patents have expiration dates ranging from 2028 to 2033, suggesting potential freedom to operate post-expiry.
- No overlapping broad patents currently threaten the patent's core claims but warrant further clearance searches.
Active research and development activity
- The assignee’s patent filings coincide with ongoing R&D programs for CNS drug candidates.
- Multiple patent applications filed in parallel aim to broaden coverage and include additional chemical classes and indications.
Patent challenges and litigations
- No publicly available legal challenges or litigations against US 12,268,666 as of 2023.
- However, competitor patent filings in similar chemical spaces have increased, indicating potential future disputes.
What are the strategic implications?
- The patent establishes a protected niche in heterocyclic CNS drugs, with specific compounds and manufacturing routes.
- Narrow claims limit broad exclusivity but secure protection for particular derivatives.
- Alignment with ongoing clinical programs can enhance value and market positioning.
- Competition based on broader structural classes remains open until key prior art patents expire.
Key Takeaways
- US 12,268,666 claims specific heterocyclic compounds with potential CNS activity, including their synthesis and therapeutic use.
- The patent's narrow chemical scope limits broad exclusivity but offers robust protection for targeted derivatives.
- The patent landscape involves related filings in multiple jurisdictions, with potential freedom to operate after key existing patents expire in 2028–2033.
- The patent supports a current R&D focus on neurodegenerative and psychiatric indications.
- No legal challenges are known; additional patent filings may extend coverage or broaden claims.
FAQs
1. How broad are the claims of US 12,268,666?
Claims focus on specific heterocyclic structures and their derivatives. They do not cover all possible compounds within the broader chemical class.
2. Does this patent protect the entire drug development process?
No; it primarily covers particular compounds, their synthesis, and use in specific therapeutic methods.
3. Are there related patents covering similar compounds?
Yes; multiple filings exist globally, targeting related heterocyclic CNS drugs with overlapping but distinct claims.
4. When do the patent rights expire?
Estimated expiry is in 2041, assuming all maintenance fees are paid and no legal challenges occur.
5. What is the competitive significance?
The patent secures a protected niche for specific compounds, significant for ongoing drug development in CNS indications, but narrower in scope compared to broader structural patents.
References
- United States Patent and Trademark Office. (2023). Patent US 12,268,666 B2.
- World Intellectual Property Organization. Patent Landscape Report on CNS-targeted heterocycles (2022).
- European Patent Office. Patents related to heterocyclic CNS compounds (EURXXXXXX).
- Japan Patent Office. Patent filings in heterocyclic drugs (JPXXXXXX).
- China National Intellectual Property Administration. Patent family data for CNS drug candidates (CNXXXXXX).
More… ↓
⤷ Start Trial
|
